(Q33737277)

29 July 2017

1 reference

title

Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators (English)

1 reference

29 July 2017

Roemer K

1

1 reference

29 July 2017

publication date

1 July 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

380

1 reference

29 July 2017

issue

7-8

1 reference

29 July 2017

page(s)

879-887

1 reference

Clues to the pathogenesis of familial colorectal cancer

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

The role of p53 in tumour suppression: lessons from mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Mechanisms of p53-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Dominant-negative p53 mutations selected in yeast hit cancer hot spots

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

In vitro analysis of the dominant negative effect of p53 mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

p53 mutants without a functional tetramerisation domain are not oncogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

p53 in embryonic development: maintaining a fine balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

A p53-dependent mouse spindle checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Gain of function mutations in p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Participation of p53 cellular tumour antigen in transformation of normal embryonic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

The p53 proto-oncogene can act as a suppressor of transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

The p53 protein is an unusually shaped tetramer that binds directly to DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of life span in human diploid fibroblasts, TIG-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Functional inactivation of genes by dominant negative mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Oncogenic forms of p53 inhibit p53-regulated gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Genetic instabilities in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Mutant p53 protein expression interferes with p53-independent apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

How p53 binds DNA as a tetramer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Sequence-specific transcriptional activation is essential for growth suppression by p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

How loops, beta sheets, and alpha helices help us to understand p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Li-Fraumeni syndrome--a molecular and clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li – Fraumeni patients carrying a mutation to the TP53 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Amphibian sex determination and sex reversal

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

An information-intensive approach to the molecular pharmacology of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

High affinity MAR-DNA binding is a common property of murine and human mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBC.1999.108

21 January 2018

Identifiers

DOI

10.1515/BC.1999.108

1 reference

29 July 2017

1 reference